Together we will beat cancer

Donate

FOCUS4: Learning from a landmark clinical trial

FOCUS4 was a large-scale trial investigating new treatments in people with advanced or metastatic colorectal cancer. Running it may not have been without its challenges, but the learnings it provided us with are invaluable if we’re to run trials like it again. 

Read More

Children’s cancer charities team up for tomorrow’s treatments

We’re helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people.

Read More

Chemo before surgery helps stop colon cancer coming back

Giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to a trial we funded.

Read More

Women in science: Cancer research pioneers – part 1

As our 20th anniversary year draws to a close, we’re celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more.

Read More

The Taylor Family Foundation gives £2.1m to support head and neck cancer research

The Taylor Family Foundation has donated £2.1m to support the Cancer Research UK PROTIS clinical trial, a study that will…

Read More

First-of-its-kind app for patients on clinical trials being piloted by Cancer Research UK

Cancer Research UK, in partnership with tech company Stitch, are going live with an app for patients to use whilst participating in a clinical trial.  

Read More

Looking back at a life-changing clinical trial

In an unusual turn of events, the results of a clinical trial for mitoxantrone turned out to be so effective that the randomisation of the trial was halted early. 

Read More

Cannabis, cannabinoids and cancer – the evidence so far

The current consensus is that, right now, there isn’t a large enough body of evidence to prove that cannabis (or any of its active compounds or derivatives) can reliably treat any form of cancer but the medical use of cannabis to treat cancer-related chronic pain is approved in the UK.

Read More

Triple negative breast cancer drug given initial ‘no’ for NHS in England

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

Read More

Aromatase inhibitors cut breast cancer recurrence in younger patients

A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.

Read More